The roles of BRCA2 in chromosome integrity

Autor: Groelly, FJ

High frequency of fork stalling and fork degradation are associated with DNA damage accumulation and represent key replication pathologies in cells lacking BRCA2. As a consequence, these cells enter mitosis with under-replicated DNA, which leads to i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1064::52c9269c9a0ff25927551d11c4fee718
https://ora.ox.ac.uk/objects/uuid:fd1cee46-28c0-48ee-9cc5-d7051023ecfe

High-resolution mapping of mitotic DNA synthesis under conditions of replication stress in cultured cells.

Autor: Groelly FJ; Genome Stability and Tumourigenesis Group, Department of Oncology, Oxford Institute for Radiation Oncology, University of Oxford, Oxford OX3 7DQ, UK., Dagg RA; Genome Stability and Tumourigenesis Group, Department of Oncology, Oxford Institute for Radiation Oncology, University of Oxford, Oxford OX3 7DQ, UK., Mailler J; Department of Molecular Biology, University of Geneva, 1205 Geneva, Switzerland., Halazonetis TD; Department of Molecular Biology, University of Geneva, 1205 Geneva, Switzerland. Electronic address: thanos.halazonetis@unige.ch., Tarsounas M; Genome Stability and Tumourigenesis Group, Department of Oncology, Oxford Institute for Radiation Oncology, University of Oxford, Oxford OX3 7DQ, UK. Electronic address: madalena.tarsounas@oncology.ox.ac.uk.

Publikováno v: STAR protocols [STAR Protoc] 2023 Mar 17; Vol. 4 (1), pp. 101970. Date of Electronic Publication: 2023 Jan 03.

Mitotic DNA synthesis is caused by transcription-replication conflicts in BRCA2-deficient cells.

Autor: Groelly FJ; Genome Stability and Tumourigenesis Group, Department of Oncology, Oxford Institute for Radiation Oncology, University of Oxford, Oxford OX3 7DQ, UK., Dagg RA; Genome Stability and Tumourigenesis Group, Department of Oncology, Oxford Institute for Radiation Oncology, University of Oxford, Oxford OX3 7DQ, UK., Petropoulos M; Department of Molecular Biology, University of Geneva, 1205 Geneva, Switzerland., Rossetti GG; Department of Molecular Biology, University of Geneva, 1205 Geneva, Switzerland., Prasad B; Genome Stability and Tumourigenesis Group, Department of Oncology, Oxford Institute for Radiation Oncology, University of Oxford, Oxford OX3 7DQ, UK., Panagopoulos A; Department of Molecular Mechanisms of Disease, University of Zurich, 8057 Zurich, Switzerland., Paulsen T; Genome Stability and Tumourigenesis Group, Department of Oncology, Oxford Institute for Radiation Oncology, University of Oxford, Oxford OX3 7DQ, UK., Karamichali A; Department of Molecular Biology, University of Geneva, 1205 Geneva, Switzerland., Jones SE; Department of Oncology, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK., Ochs F; Department of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, UK., Dionellis VS; Department of Molecular Biology, University of Geneva, 1205 Geneva, Switzerland., Puig Lombardi E; Genome Stability and Tumourigenesis Group, Department of Oncology, Oxford Institute for Radiation Oncology, University of Oxford, Oxford OX3 7DQ, UK., Miossec MJ; Bioinformatics and Statistical Genetics Core, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK., Lockstone H; Bioinformatics and Statistical Genetics Core, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK., Legube G; LBCMCP, Centre de Biologie Intégrative (CBI), CNRS, Université de Toulouse, UT3, Toulouse 31062, France., Blackford AN; Department of Oncology, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK., Altmeyer M; Department of Molecular Mechanisms of Disease, University of Zurich, 8057 Zurich, Switzerland., Halazonetis TD; Department of Molecular Biology, University of Geneva, 1205 Geneva, Switzerland. Electronic address: thanos.halazonetis@unige.ch., Tarsounas M; Genome Stability and Tumourigenesis Group, Department of Oncology, Oxford Institute for Radiation Oncology, University of Oxford, Oxford OX3 7DQ, UK. Electronic address: madalena.tarsounas@oncology.ox.ac.uk.

Publikováno v: Molecular cell [Mol Cell] 2022 Sep 15; Vol. 82 (18), pp. 3382-3397.e7. Date of Electronic Publication: 2022 Aug 23.

A transcription-based mechanism for oncogenic β-catenin-induced lethality in BRCA1/2-deficient cells.

Autor: Dagg RA; Genome Stability and Tumourigenesis Group, MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK., Zonderland G; Genome Stability and Tumourigenesis Group, MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK.; Center for Chromosome Stability, Institute for Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Lombardi EP; Genome Stability and Tumourigenesis Group, MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK., Rossetti GG; Department of Molecular Biology, University of Geneva, Geneva, Switzerland., Groelly FJ; Genome Stability and Tumourigenesis Group, MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK., Barroso S; Centro Andaluz de Biología Molecular y Medicina Regenerativa (CABIMER), Universidad de Sevilla-Consejo Superior de Investigaciones Científicas-Universidad Pablo de Olavide, Seville, Spain., Tacconi EMC; Genome Stability and Tumourigenesis Group, MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK., Wright B; Bioinformatics and Statistical Genetics Core, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK., Lockstone H; Bioinformatics and Statistical Genetics Core, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK., Aguilera A; Centro Andaluz de Biología Molecular y Medicina Regenerativa (CABIMER), Universidad de Sevilla-Consejo Superior de Investigaciones Científicas-Universidad Pablo de Olavide, Seville, Spain., Halazonetis TD; Department of Molecular Biology, University of Geneva, Geneva, Switzerland., Tarsounas M; Genome Stability and Tumourigenesis Group, MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK. madalena.tarsounas@oncology.ox.ac.uk.

Publikováno v: Nature communications [Nat Commun] 2021 Aug 13; Vol. 12 (1), pp. 4919. Date of Electronic Publication: 2021 Aug 13.

BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors.

Autor: Reisländer T; Genome Stability and Tumourigenesis Group, The CR-UK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford, OX3 7DQ, UK., Lombardi EP; Institut Curie, PSL Research University, CNRS, UMR3244, F-75005, Paris, France.; Sorbonne Universités, UPMC Univ Paris 06, CNRS, UMR3244, F-75005, Paris, France., Groelly FJ; Genome Stability and Tumourigenesis Group, The CR-UK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford, OX3 7DQ, UK., Miar A; Hypoxia and Angiogenesis Group, Weatherall Institute of Molecular Medicine, Department of Oncology, University of Oxford, Oxford, OX3 9DS, UK., Porru M; Area of Translational Research, IRCCS Regina Elena National Cancer Institute, 00144, Rome, Italy., Di Vito S; Area of Translational Research, IRCCS Regina Elena National Cancer Institute, 00144, Rome, Italy., Wright B; Bioinformatics and Statistical Genetics Core, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK., Lockstone H; Bioinformatics and Statistical Genetics Core, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK., Biroccio A; Area of Translational Research, IRCCS Regina Elena National Cancer Institute, 00144, Rome, Italy., Harris A; Hypoxia and Angiogenesis Group, Weatherall Institute of Molecular Medicine, Department of Oncology, University of Oxford, Oxford, OX3 9DS, UK., Londoño-Vallejo A; Institut Curie, PSL Research University, CNRS, UMR3244, F-75005, Paris, France.; Sorbonne Universités, UPMC Univ Paris 06, CNRS, UMR3244, F-75005, Paris, France., Tarsounas M; Genome Stability and Tumourigenesis Group, The CR-UK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford, OX3 7DQ, UK. madalena.tarsounas@oncology.ox.ac.uk.

Publikováno v: Nature communications [Nat Commun] 2019 Jul 17; Vol. 10 (1), pp. 3143. Date of Electronic Publication: 2019 Jul 17.